



Subject: Gonadotropin-releasing hormone agonists and antagonists (leuprolide and others)*

Effective Date: May 1, 1999

Department(s) Utilization Management

Policy: Leuprolide (Lupron) or other injectable or implantable GnRH analogs are reimbursable for medically necessary indications delineated in this policy, under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement and to limit reimbursement for a class of drugs to medically necessary indications.

Procedure:

1. Reimbursable indications for Leuprolide or other GnRH analogs include, but are not limited to, the following:

- Management of infertility (**ICD-9 628.0 – 628.9; ICD-10 N97.0-N97.9**) leuprolide, cetorelix(Cetrotide), ganirelix
- Prostatic cancer (**ICD-9 185; ICD-10 C61**) leuprolide, histrelin(Vantas), triptorelin(Trelstar), degarelix(Firmagon), goserelin
- Endometriosis (**ICD-9 617.0 – 617.9; ICD-10 N80.0-N80.9**) goserelin(Zoladex), leuprolide, triptorelin
- Uterine leiomyomata (**ICD-9 218.0 – 218.9; ICD-10 D25.0-D25.9**) leuprolide, triptorelin
- Polycystic ovary syndrome (**ICD-9 256.4; ICD-10 E28.2**) Leuprolide

- Central precocious puberty (**ICD-9 259.1; ICD-10 E30.1**) leuprolide, histrelin(Supprelin LA), triptorelin
- Dysfunctional uterine bleeding (**ICD-9 626.8; ICD-10 N89.7, N92.5, N93.8**) goserelin
- Premenopausal breast cancer (ICD-9 174-174.5; ICD-10 C50-C50.31) TNM stages pT1, pT2, or pT3 and pN0 or pN1mi, that is ER/PR positive, when used in combination with tamoxifen or an aromatase inhibitor as adjuvant endocrine therapy (goserelin and leuprolide)
- Metastatic breast cancer (**ICD-9 174.9; ICD-10 C50.911-C50.919**) leuprolide, goserelin
- Relapsed ovarian granulosa cell tumors (**ICD-9 183.2; ICD-10 C56.1-C56.9**) Leuprolide
- Recurrent ovarian cancer, fallopian and primary peritoneal cancer(**ICD-9 183.0,183.2,158.8-158.9; ICD-10 C56.1-C56.9, C57.00-C57.02, C45.1, C48.1-C48.8**) Leuprolide.

2. All requests for Leuprolide and other GnRH analogs must undergo medical review except when they are prescribed for management of infertility.

References

Klein KO, Lee PA. Gonadotropin-Releasing Hormone (GnRHa) Therapy for Central Precocious Puberty (CPP): Review of Nuances in Assessment of Height, Hormonal Suppression, Psychosocial Issues, and Weight Gain, with Patient Examples. *Pediatr Endocrinol Rev.* 2018 ;15(4):298-312(Apr)

Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. *Cochrane Database Syst Rev.* 2017;11:CD000547(Nov)

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Ovarian Cancer Including Fallopian Tube cancer and Primary Peritoneal cancer Version 2.2015; 2.2018 accessed online at nccn.org

National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer Version 2.2016; 2.2018 accessed at nccn.org

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Breast Cancer Version 2.2016; 1.2018 at nccn.org.

Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. *Obstet Gynecol.* 2015;126(1):187-95(Jul)

Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F, Selvaggi LE. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). *Reprod Biol Endocrinol.* 2012;10:26(Apr)

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Ovarian Cancer Including Fallopian Tube cancer and Primary Peritoneal cancer Version 1.2013. accessed online 01/09/13 at nccn.org

Chen I, Motan T, Kiddoo D. Gonadotropin-releasing hormone agonist in laparoscopic myomectomy: systematic review and meta-analysis of randomized controlled trials.2011 *J Minim Invasive Gynecol*;18(3):303-9(May-Jun)

Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.2012 *Int J Urol*;19(7):594-601(Jul)

Bhatia K, Doonan Y, Giannakou A, *et al.* A randomised controlled trial comparing GnRH antagonist cetrorelix with GnRH agonist leuprorelin for endometrial thinning prior to transcervical resection of endometrium. *BJOG* 2008;115(10):1214-1224 (Sep)

Shahani S, Braga-Basaria M, Basaria S. Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis. *J Clin Endocrinol Metab* 2008;93(6):2042-2049 (Jun)

Pasquino AM, Pucarelli I, Accardo F, *et al.* Long-Term Observation of 87 Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogs: Impact on Adult Height, Body Mass Index, bone Mineral Content, and Reproductive Function. *J Clin Endocrinol Metab* 2008;93(1):190-195 (Jan)

Eugster EA, Clarke W, Kletter GB, *et al.* Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial. *J Clin Endocrinol Metab* 2007;92(5):1697-1704 (May)

Garibaldi L. Disorders of Pubertal Development. Ch 563 in Kliegman RM, Behrman RE, Jenson HB, *et al.* *Nelson Textbook of Pediatrics.* 18th ed. Philadelphia. Saunders Elsevier. 2007

Higano C. Androgen Deprivation Therapy: Monitoring and Managing the Complications. *Hematol/Oncol Clin N Amer* 2006;20(4):909-923 (Aug)

-----Leuprolide: Drug Information. *UpToDate OnLine* 13.3 (2006) www.uptodate.com

Buggs D, Rosenfield RL. Polycystic ovary syndrome in adolescence. *Endocrinol Metab Clin N Amer* 2005;34(3):677-705 (Sep)

Mahutte NG, Arici A. Medical management of endometriosis-associated pain. *Obstet Gynecol Clin N Amer* 2003;30(1):133-150 (Mar)

Drafted By/Date: L. Vogel, MD 03/99

Approved By/Date: QM Committee 4/27/99

Revised By/Date: B. Fisher, MD 02/22/06

Approved By/Date: QM Committee 03/28/06

Revised By/Date: B. Fisher, MD, E. Minaya, MD 10/30/08

Approved By/Date: QM Committee 12/09/08

Reviewed w/o Revision By/Date: MMcNeil MD 11/29/10

Approved By/Date: QMC, 01/25/11

Revised By/Date: MMcNeil, MD 01/09/13

Approved By/Date: QM Committee 1/22/13

Revised By/Date: M McNeil, MD 06/23/16

Approved By/Date: QM Committee 08/23/16

Revised By/Date: M. McNeil, MD 10/04/16

Approved By/Date: QM Committee 10/25/16

Revised By/Date: M McNeil, MD 06/05/18

Approved By/Date: QM Committee 06/19/18

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.